Drugmaker GSK's Arexvy vaccine, as well as vaccines from Pfizer and Moderna, are already approved for use in adults 60 and older, since age brings higher risk from RSV disease. Arexvy is the first ...
The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday ...
The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker ...
The Arexvy respiratory syncytial virus (RSV) vaccine, which is already approved for adults 60 and up, is now indicated for use in people ages 50 to 59 years old thanks to recent Food and Drug ...
The vaccine is approved for at-risk adults in their fifties, making it the first shot approved for the age group. Engadget ...
June 8 (UPI) --The U.S. Food and Drug Administration approved GSK's respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the shot's accessibility to younger patients.
GSK (NYSE:GSK) announced late Friday that the U.S. FDA approved Arexvy, its vaccine against the respiratory syncytial virus (RSV) for adults aged 50–59 years at increased risk of infection ...